- Home
- COPR vs MREO Comparison
COPR vs MREO Comparison
Compare COPR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COPR | MREO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 50.3M |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | COPR | MREO |
|---|---|---|
| Price | $2.35 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $1.97 |
| AVG Volume (30 Days) | 70.3K | ★ 1.1M |
| Earning Date | 12-01-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $609,174.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $0.20 |
| 52 Week High | $4.16 | $2.37 |
Technical Indicators
Market Signals| Indicator | COPR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 25.16 | 37.34 |
| Support Level | $2.05 | $0.27 |
| Resistance Level | $3.63 | $0.35 |
| Average True Range (ATR) | 0.30 | 0.03 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 8.11 | 0.40 |
Price Performance
Historical ComparisonAbout COPR Idaho Copper Corporation Common Stock
Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).